Pierre Maheux
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
Journal: Cardiovascular research
Published: March 26, 2024
Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15.
Journal: Journal of atherosclerosis and thrombosis
Published: January 14, 2024
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
Journal: Circulation
Published: October 18, 2023
Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18.
Journal: JACC. Asia
Published: June 06, 2023
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
Journal: Journal of the American College of Cardiology
Published: June 01, 2023
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Journal: The lancet. Diabetes & endocrinology
Published: October 19, 2022
Effects of Changing the Amount and Source of Dietary Carbohydrates on Symptoms and Dietary Satisfaction Over a 1-Year Period in Subjects with Type 2 Diabetes: Canadian Trial of Carbohydrates in Diabetes (CCD).
Journal: Canadian journal of diabetes
Published: January 07, 2015
Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
Journal: Current medical research and opinion
Published: October 02, 2012
Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study.
Journal: Clinical endocrinology
Published: June 29, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026